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Abstract In recent years, stem cell nanotechnology has
emerged as a new exciting ﬁeld. Theoretical and experi-
mental studies of interaction between nanomaterials or
nanostructuresandstemcellshavemadegreatadvances.The
importance of nanomaterials, nanostructures, and nano-
technology to the fundamental developments in stem cells-
based therapies for injuries and degenerative diseases has
been recognized. In particular, the effects of structure and
properties of nanomaterials on the proliferation and differ-
entiation of stem cells have become a new interdisciplinary
frontier in regeneration medicine and material science. Here
we review some of the main advances in this ﬁeld over the
pastfewyears,exploretheapplicationprospects,anddiscuss
the issues, approaches and challenges, with the aim of
improving application of nanotechnology in the stem cells
research and development.
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Introduction
Stem cells and nanotechnology are two different ﬁelds
with the characterization of rapid development, highly
interdisciplinary, and controversial. So far the two ﬁelds
intercross and gradually form a new emerging ﬁeld, that
is, nanotechnology in stem cells or stem cell nanotech-
nology, which refers to the application of nanotechnology
in stem cells research and development [1, 2]. Stem cells
are the parent cells of all tissues and organs of the body
and exist mainly to maintain and replace the cells in the
areas where they are found such as blood, bone marrow,
skin, muscle and organs like the brain, liver, etc. [3–6].
Stem cells are classiﬁed into two kinds, that is, embryonic
stem cells (ESCs) and adult stem cells. ESCs is composed
of somatic stem cells that are restricted to a set of lineages
and normally arise from the tissue from which they are
derived. Adult stem cells are not pluripotent but multi-
potent, which differentiate only into a limited variety of
cell types [7, 8]. Since Evans, et al. [9] ﬁrstly reported the
isolated ESCs in 1981, stem cells research have become a
novel hotspot and provide a new chance for regenerative
medicine, as shown in Fig. 1, the pluripotential nature of
ES cells to differentiate into cell types of all three primary
germ lineages exhibit attracting prospect for stem cells-
based therapy for human injuries and degenerative dis-
eases [10, 11]. Especially induced pluripotent stem cells
(ips) was successfully established in 2007, which provided
great progress for controllable man-made stem cells [12–
14]. However, several obstacles must be overcome before
their therapeutic application can be realized. These
include the development of advanced techniques to
understand and control functions of microenvironmental
signals and novel methods to track and guide transplanted
stem cells [15–18].
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DOI 10.1007/s11671-009-9292-zNanotechnology brings new chance to stem cells
research and development. Nanotechnology is the term
used to cover the design, construction, and utilization of
functional structures with at least one characteristic
dimension measured in nanometers [19, 20]. Such materi-
als and systems can be designed to exhibit novel and
signiﬁcantly improved physical, chemical, and biological
properties, phenomena and processes as a result of the
limited size of their constituent particles or molecules. The
reason for such interesting and very useful behavior is that
when characteristic structural features are intermediate in
extent between isolated atoms and bulk macroscopic
materials, i.e., in the range of about 0.1–100 nm, the
objects may display physical attributes substantially dif-
ferent from those displayed by either atoms or bulk
materials. It is well-known that the nanomaterials own four
basic unique effects such as small size effects, surface
effects, quantum size effects, and tunnel effects, and ulti-
mately these effects can lead to new technological
opportunities as well as new challenges [21–23]. The
application of nanomaterials and nanotechnology in stem
cells research and development exhibits attracting techno-
logical prospects, which provide a new chance to solve
current problems that stem cells research and development
meet.
In particular, the effects of structure and properties of
nanomaterials on the proliferation and differentiation of
stem cells have become a new interdisciplinary frontier in
regeneration medicine and material science [24, 25]. Here
we review some of the main advances in this ﬁeld over the
past few years, explore the application prospects, and dis-
cuss the issues, approaches, and challenges, with the aim of
Fig. 1 Establishment of human ESCs (hESCs) showing (a–f) early
stages of human embryo development, (g) established hESCs line. In
vitro differentiation of hESCs toward hepatocyte-like cells showing
(h) hESCs derived embryoid bodies, (i–j) hematopoietic differenti-
ation, (k) endothelia differentiation, (l) neuron differentiation, (m)
hepatocytes differentiation, (n) ips cells
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123improving application of nanotechnology in the stem cell
research and development.
Advance of Stem Cell Nanotechnology
In recent years, the application of nanotechnology in stem
cell research and development have made great progress.
For example, magnetic nanoparticles (MNPs) have been
successfully used to isolate and sort stem cells [26],
quantum dots have been used for molecular imaging and
tracing of stem cells [27], nanomaterials such as carbon
nanotubes (CNTs) [28], ﬂuorescent CNTs [29] and
ﬂuorescent MNPs [30], etc. have been used to deliver gene
or drugs into stem cells, unique nanostructures were
designed for controllable regulation of proliferation and
differentiation of stem cells, and all these advances speed
up the development of stem cells toward the application in
regenerative medicine.
Application of Magnetic Nanoparticles in Isolation
of Stem Cells
Magnetic nanoparticles (MNPs), as shown in Fig. 2,a
series of magnetism-engineered iron oxide nanoparticles
were developed [31], because of their superparamagnetic
Fig. 2 Magnetism-engineered iron oxide (MEIO) nanoparticles and
effects of their magnetic spin on MRI. a TEM images of MnFe2O4
(MnMEIO), Fe3O4 (MEIO), CoFe2O4 (CoMEIO), and NiFe2O4
(NiMEIO). All nanoparticles were synthesized to be *12 nm with
narrow size distributions (0 \ *8%). Scale bar, 50 nm. b Mass
magnetization values of MFe2O4 nanoparticles. In face-centered cubic
latticesofoxygen,themagneticspinsatOnsitesalignedinparallelwith
the direction of the external magnetic ﬁled whereas those at Td sites
aligned antiparallel. MnFe2O4 had the highest mass magnetization
value, with a magnetic spin magnitude of 5 lg( e, f) T2-weighted spin
echo MR images, their color maps and relaxivity (R2) of a series of
MEIOnanoparticles at1.5 T.Inf,theR2ofCLIOisalsopresented, for
comparison. Consistent with the mass magnetion results, MnMEIO
showed the strongest MR contrast effect (that is, darkest MR image,
violet in color map) and had the highest R2 coefﬁcient. Mass
magnetization value, MR contrast and R2 coefﬁcient gradually
decreased as M2? changed from Mn
2? to Fe
2?,t oC o
2? and to Ni
2?
[31]
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123property, have been widely explored potentials in appli-
cations such as hyperthermia [32], magnetic resonance
imaging (MRI) [31], tissue repair [33], immunoassay [34],
drug/gene delivery [35], cell separation [26], etc. Stem
cells is a unlimited cell source in stem cell therapy, the key
challenge is how to isolate stem cells from a multi-type cell
mixture at a low cost, fast, and easily operated fashion. So
far some reports show that MNPs can directly label stem
cells, and then labeled stem cells were isolated by magnetic
force or ﬂow cytometry. For example, Jing, et al. [26]
reported that MNPs combined with Cd34 antibody, suc-
cessfully enriched peripheral blood progenitor cells
(PBPCs) from human blood circulation. They tested
CD34? cell immunomagnetic labeling and isolation from
fresh leukocyte fraction of peripheral blood using the
continuous quadrupole magnetic ﬂow sorter (QMS), con-
sisting of a ﬂow channel and a quadrupole magnet with a
maximum ﬁeld intensity of 1.42 T and a mean force ﬁeld
strength of 1.45 9 10
8 TA/m
2. Seven commercial pro-
genitor cell labeling kits were quantitatively evaluated by
measuring magnetophoretic mobility of a high CD34
expression cell line, KG-1a, using the cell tracking velo-
cimeter (CTV). The commercial CD34 progenitor cell
isolation kit from Miltenyi Biotec and Bergisch Gladbach
in Germany was used to enrich the progenitor cells from 11
fresh and 11 cryopreserved clinical leukapheresis samples
derived from different donors. Results showed that the KG-
1a cells were strongly labeled, the CD34? cells were
isolated with a purity of 60–96%, a recovery of 18–60%, an
enrichment rate of 12–16%, and a throughput of (1.7–
9.3) 9 10
4 cells/s. Main parameters fall well within the
clinical useful range. These isolated CD34 progenitor cells
can be used for patient therapy.
Application of Nanoparticles in Imaging and Tracing
of Stem Cells
Up-to-date, nanoparticles such as quantum dots, MNPs, and
gold nanorods can be used for imaging and tracing of stem
cells [27, 31, 36–38]. For example, quantum dots have been
subject to intensive investigations due to their unique
properties and potential application prospects. QDs have
been used successfully in cellular imaging [39], immuno-
assays [40], DNA hybridization [41], and optical barcoding
[42]. Quantum dots provide a new functional platform for
bioanalytical sciences and biomedical engineering. Ohyabu
et al. [27] reported that quantum dots conjugated with an
antibody against mortalin protein, resulting in the formation
of i-QD composites, which can be internalized by mesen-
chymal stem cells (MSCs), and ﬁnally labeled MSCs cells.
The i-QD labeled MSCs underwent normal adipocyte,
osteocyte, and chondrocyte differentiation in vitro and
in vivo, which highly suggest that i-QDs can be applied to
in vivo imaging diagnostics and tracing of stem cells in the
distribution of mouse body. As shown in Fig. 3, QDs can be
designed as multi-functional nanoprobes, which can be
modiﬁed with different biomolecules such as liposome,
PEG, peptides, or antibody, and own speciﬁc functions, can
be used for molecular imaging, gene or drug delivery and
molecule tracing [40].
Besides quantum dots, MNPs were also used for
molecular imaging and tracing of stem cells [31, 43]. For
example, superparamagnetic iron oxide nanoparticles
(SPIO) have been used for stem cell labeling, MRI, and
tracking of transplanted stem cells [44]. For example,
ﬂuorescent molecules were covalently linked to dextran-
coated iron oxide nanoparticles to characterize HSCs
labeling to monitor the engraftment process [45]. Conju-
gating ﬂuorophores to the dextran coat for ﬂuorescence-
activated cell sorting puriﬁcation eliminated spurious sig-
nals from nonsequestered nanoparticle contaminants. A
short-term deﬁned incubation strategy was developed that
allowed efﬁcient labeling of both quiescent and cycling
HSCs, with no discernable toxicity in vitro or in vivo.
Transplantation of puriﬁed primary human cord blood
lineage-depleted and CD34
? cells into immunodeﬁcient
mice allowed detection of labeled human HSCs in the
recipient bones. Flow cytometry was used to precisely
quantitate the cell populations that had sequestered the
nanoparticles and to follow their fate post-transplantation.
Flow cytometry endpoint analysis conﬁrmed the presence
of MNPs-labeled human stem cells in the marrow [46]. The
use of stem cell therapy in different disorders of the central
nervous system (CNS) has been extensively examined.
Endorem-labeled GFP? MSCs were grafted into rats in an
experimental model of stroke [46]. The cells were grafted
either intracerebrally into the hemisphere contralateral to
the lesion, or intravenously into the femoral vein. Rats with
grafted stem cells were examined weekly for a period of
3–7 weeks post-transplantation using a 4.7-T Bruker
spectrometer. The lesion was visible on MR images as a
hyperintense signal. One week after grafting, a hypointense
signal was found in the lesion, which intensiﬁed during the
second and third weeks, regardless of the route of admin-
istration. Its intensity corresponded to Prussian blue
staining or GFP labeling. MSCs labeled with Endorem
were also injected intravenously into the femoral vein
1 week after a transversal spinal cord lesion [43, 47]. MR
images of longitudinal spinal cord sections from lesioned
non-grafted animals showed the lesion cavity as inhomo-
geneous tissue with a strong hyperintensive signal. Lesions
of grafted animals were seen as dark hypointense areas.
Histological evaluation conﬁrmed only a few iron-con-
taining cells in lesioned, control animals, but strong
positivity for iron in grafted animals. Compared to control
rats, in grafted animals the lesion, which was populated by
596 Nanoscale Res Lett (2009) 4:593–605
123grafted MSCs, was considerably smaller, suggesting a
positive effect of the MSCs on lesion repair [48]. Several
successful applications of MR tracking can be found in
other organs, such as the heart [49], liver [50], kidney [51],
and pancreatic islets [52]. It is reported that surface mod-
iﬁcation of MNPs with D-mannose, poly-L-Lysin (PLL) or
polydimethylacrylamid (PDMAAm) resulted in better
labeling efﬁciency than that seen with dextran-coated
SPIO.
We also observed that ﬂuorescent MNPs (FMNPs) [53]
could conjugate with brcaa1 antibody, and formed brcaa1
antibody-labeled FMMNP probes. We also observed that
BRCAA1 protein exhibited over-expression in ES CCE
cells. As shown in Fig. 4e, while the prepared probes
incubated with ES CCE cells for 30 min, the prepared
probes can be internalized into CCE stem cells. Because of
the internalized probes own superparamagnetic properties,
these stem cells with ﬂuorescent signals can be isolated
directly under in vitro magnetic ﬁelds, and also can be
traced (unpublished data). We also observed that the QDs
covered CNTs can be internalized into stem cells, and
realized labeling stem cells [28].
Application of Nanoparticles in Gene Delivery Systems
for Stem Cells
Generating progenitor cells with in vivo reconstitution
functions has been at the center of intense research to
Fig. 3 Various designs of multimodal QD probes. a, b Quantum dots
having different molecules for target-speciﬁc interaction, and,
attached to the surface, paramagnetic lipids, and chelators for
nuclear-spin labeling. c The silica sphere has QDs and paramagnetic
nanoparticles inside and target-speciﬁc groups attached to the outside.
d The structure of a multimodal QD probe, based on silica-shelled
single-QD micelles [40]
Nanoscale Res Lett (2009) 4:593–605 597
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(ESCs) for the treatment of debilitating genetic, traumatic,
and degenerative conditions [54]. A major challenge for
clinical development of these pluripotent cells is effective,
non-invasive imaging of transplanted cells to monitor
biodistribution (i.e., in vivo tracking). Furthermore,
reproducible approaches need to be developed enabling
efﬁcient intracellular delivery of biomolecules, including
DNA, RNA, peptides, or proteins, required to control ES
cell differentiation. Physical methods such as electropora-
tion and nucleofection offer the advantage of high delivery
efﬁciency but frequently cause severe damage to ES cells
[55]. Viral vectors, including retro-, lenti-, and adenovi-
ruses, result in successful transfection and reproducible
manipulation of ES differentiation in vitro [56]. However,
the risk of toxicity, immunogenicity, and increased muta-
genesis signiﬁcantly decrease clinical viability of these
viral carriers for biomedical applications. Therefore, non-
viral vectors such as polymeric nanoparticles and lipo-
somes are currently pursued as the most promising
nanotechnology platform to translate exciting laboratory
ﬁndings with ES cells into clinically viable applications
[57, 58].
We found that No. 5 generation of polyamidoamine
dendrimer-functionalized ﬂuorescent multi-walled carbon
nanotubes (dMNTs) can enter into mice embryonic stem
cell line CCE highly efﬁciently [28]. More than 20 lg/mL
dose can cause ES cells become smaller and smaller as the
incubation time increases, and inhibit cell growth in dose-
and time-dependent means, less than 5 lg/mL dose can
improve ES differentiation. Dendrimers is a novel special
class of organic molecules: they can take different func-
tional groups through a series of chemical modiﬁcations,
and their interior cavities can serve as storage areas for a
lot of genes or drugs [59]. Dendrimers may be a good
nonviral delivery vector because it has the advantages of
simplicity of use, and ease of mass production compared
with viral vectors that are inherently risky for clinical use.
Polyamidoamine (PAMAM) dendrimer-modiﬁed MNPs
can markedly enhance gene delivery efﬁciency [60–62].
The prepared dMNTs may be a highly efﬁcient gene
delivery system for ES cells, have potential applications in
ES research. As shown Fig. 5, nanoparticles such as MNPs
[37, 49] and quantum dots can enter into human MSCs
cells, and can keep longer time inside ES cells. As shown
in Fig. 5d, i, j, and k, we observed that SiO2 wrapped CdTe
nanoparticles can enter into murine stem cells, and exist in
those induced-differentiated neurons cells, hematopoietic
cells and endothelia cells, and did not exhibit cytotoxicity
within the used concentration.
As shown in Fig. 5a, b, and c, MNPs entered into ES
cells, and also can be used to trace ES cells in the whole
body of mouse. As shown in Fig. 5l, m, n, and o, we can
clearly observe that those grafted stem cells with MNPs
formed teratomas composed of tissues of all three germ
layers [44].
More recently, a molecular delivery system by using
atomic force microscopy (AFM) and nanoneedle has been
developed to transfer gene into living cells [63]. Han et al.
described a low-invasive gene delivery method that uses an
etched AFM tip or nanoneedle that can be inserted into a
cell nucleus without causing cellular damage. The nano-
needle is 200 nm in diameter and 6 lm in length and is
operated using an AFM system. The probabilities of
insertion of the nanoneedle into human MSCs and human
embryonic kidney cells (HEK293) were higher than those
of typical microinjection capillaries. A plasmid containing
the green ﬂuorescent protein (GFP) gene was adsorbed on a
poly-L-lysine-modiﬁed nanoneedle surface, which was then
inserted into primary cultured single human MSCs. A
highly efﬁcient gene delivery of over 70% was achieved in
human MSCs, which compared very favorably with other
major nonviral gene delivery methods (lipofection *50%
and microinjection *10%).
Fig. 4 TEM images of a FMCNPs b MNPs and c quantum dots. d
FMCNPs are aligned in a magnetic ﬁeld obtained with a ﬂuorescent
microscope3. The arrows are added to clearly show the orientation of
the magnetic ﬁeld. The inset image is obtained without a magnetic
ﬁled. e Fluorescent microscope image of FMCNPs inside murine
ECC stem cells, scale bar: 10 lm[ 53]
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123Effects of CNTs on Proliferation and Differentiation
of Stem Cells
Carbon nanotubes, because of unique mechanical, physical,
and chemical properties, have great potential applications
in various ﬁelds including molecular electronics, medical
chemistry, and biomedical engineering [64–72]. Carbon
nanotubes can be functionalized to achieve improved
properties and functions such as biocompatibility and
biomolecular recognition capabilities [73, 74]. Protein-
conjugated CNTs can move across the cellular membrane
and enter into cytoplasm and cell nucleus [75, 76]. Carbon
nanotubes can be ﬁlled with DNA or peptide molecules,
have high potential in gene or peptide storage, and delivery
system in molecular therapy of diseases [57]. In our pre-
vious work, we investigated the effects of single walled
carbon nanotubes (SWCNTs) on human embryonic kidney
cell line HEK293 cells [77]. We observed that SWCNTs
can inhibit HEK293 cell proliferation, and decrease cell
adhesive ability in a dose- and time-dependent manner.
HEK293 cells exhibit active responses to SWCNTs such as
secretion of some 20–30 kd proteins to wrap SWCNTs,
aggregation of cells attached by SWCNTs, and formation
of nodular structures. As shown in Fig. 6, cell cycle anal-
ysis showed that 25 lg/mL SWCNTs in medium induced
G1 arrest and cell apoptosis in HEK293 cells. Biochip
analysis showed that SWCNTs can induce up-regulation
expression of cell cycle-associated genes such as p16, bax,
p57, hrk, cdc42, and cdc37, down-regulation expression of
cell cycle genes such as cdk2, cdk4, cdk6, and cyclin D3,
and down-regulation expression of signal transduction-
associated genes such as mad2, jak1, ttk, pcdha9, and erk.
Western blot analysis showed that SWCNTs can induce
down-regulation expression of adhesion-associated pro-
teins such as laminin, ﬁbronectin, cadherin, FAK, and
collagen IV. SWCNTs inhibit HEK293 cell growth by
inducing cell apoptosis and decreasing cellular adhesion
ability. It is also observed that SWCNTs stimulate human
osteoblast cells and human ﬁbroblast cells to appear many
protuberance on the surface compared with the control,
which is one kind of active protective reaction of stimu-
lated cells. Regarding the mechanism of nanoparticles such
as CNTs, etc., entering into cells, receptor-mediated
endocytosis may be responsible for the phenomena, a
Fig. 5 Drawing and transmission electron microscopy (TEM) image
(a) and Prussian blue-positive cells (b) showing nanoparticles inside
the cell (arrow). c: T2-weighted image of a rat spinal cord injected
with nanoparticle-labeled MSCs. Arrowheads mark the injection sites,
arrow the lesion populated with cells; Implanted nanoparticles labeled
mouse ESCs were labeled with SPIO (e–g). Cells were grafted
intravenously. In vivo MRI was used to track their fate (h). Prussian
blue staining conﬁrmed the presence of iron oxide nanoparticles
inside the cells (f). After 4 weeks post-implantation, grafted cells
migrated to the lesion site and formed teratomas composed of tissue
of all three germ layers (l–m); In vitro differentiation of quantum dots
labeling of hESCs (d) into neurons (i), hematopoietic cells (j) and
endothelia cells (k)[ 44]
Nanoscale Res Lett (2009) 4:593–605 599
123theory model is also suggested, the optimal size of particles
entering into cells is between 25 nm and 700 nm or so, too
small nanoparticles are very difﬁcult to enter into cells
because of cellular surface tension force and adhesion. The
further mechanism of effects of CNTs on human ES cells is
being investigated from the following four scales such as
molecular, cellular, animals, and environment levels.
Crouse et al. [78] investigated effects of a range of
different types of CNTs, including single walled nanotubes
(SWCNTs), multi-walled nanotubes (MWCNTs) and
functionalized CNTs on hMSCs, and revealed that at low
concentrations of COOH functionalized SWCNTs, the
CNTs had no signiﬁcant effect on cell viability or prolif-
eration. In addition, by ﬂuorescently labeling the COOH
functionalized SWCNTs, the CNTs were seen to migrate to
a nuclear location within the cell after 24 h, without
adversely affecting the cellular ultrastructure. Moreover,
the CNTs had no effect on adipogenesis, chondrogenesis,
or osteogenesis. So far CNTs was considered to be one
novel and emerging technology in gene or drug delivery,
tissue engineering, and regenerative medicine. At low
concentrations, CNTs have minimal affect on MSCs via-
bility and multipotency [79–81]. Therefore, they have great
potential to advance the ﬁeld in a number of ways
including: (1) Development of nanovehicles for delivering
biomolecule-based cargos to MSCs; and (2) Creation of
novel biomedical applications for electroactive CNTs in
combination with MSCs. Since CNTs are electrically
conductive, there is a huge potential for the manipulation
of MSCs differentiation pathways to create electroactive
cells such as those found in the heart. In particular, speciﬁc
applications could result in novel MSCs based cell thera-
pies for electroactive tissue repair; novel biomolecule
delivery vehicle for manipulation of MSCs differentiation
Fig. 6 Apoptosis of HEK293 cells induced by SWCNTs. a morpho-
logical changes of HEK293 cells cultured with 25 lg/mL SWCNTs
for 3 days; a0: showing cells become round and ﬂoating with
apoptotic characterizatics; control: showing normal morphological
cells; a1: showing nodular structure composed of SWCNTs and
apoptotic cells; a2: showing apoptotic cells attached by SWCNTs. b1:
DNA electrophoresis of cells cultured with 25 lg/mL SWCNTs for
1–5 days, M: molecular Marker; no. 1–5 denote the results of cells
cultured for day 1–5, respectively; b2: DNA electrophoresis results of
control cells cultured for day 1–5; c: the cell cycle distribution of
HEK293 cells cultured with 25 lg/mL SWCNTs for 4 days, the
percentage of sub-G1 cells (apoptosis cells) was 43.5% [77]
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123pathways; and electroactive CNT scaffolds for damaged
electroactive tissues.
Application of 3D Nanostructures in Stem Cell Tissue
Engineering
The combination of stem cells with tissue engineering
principles enables developing the stem cell-based thera-
peutic strategy for human diseases. Stem cell and
progenitor cell directional differentiation is currently one
hotspot, the differentiation of stem cells that conjugate 3D
materials is considered as the most perspective tissue
engineering. Up to date, various micro-/nanofabrication
technologies have been used to guide stem cells to develop
into 3D biodegradable scaffolds [82, 83]. Nanostructured
scaffolds are designed to trigger stem cells to become
speciﬁc cell types compromising the tissues and organs in
the body. Inside these scaffolds, cells deposit their own
matrix and as the scaffold degrades, they form a 3D tissue
structure that mimics the body’s natural tissues. For
example, Gelain et al. [84] reported that they had devel-
oped a 3D cell culture system using a designer peptide
nanoﬁber scaffold with mouse adult neural stem cells. They
synthesized 18 different peptides which directly incorpo-
rate various functional motifs to promote cell adhesion,
differentiation, and bone marrow homing activities. These
functionalized peptides self-assemble into nanoﬁber scaf-
folds where cells can be fully embedded by the scaffold in
3D. Without addition of soluble growth factors and neu-
rotrophic factors, two of these scaffolds functionalized with
bone marrow homing motifs not only signiﬁcantly
enhanced survival of the neural stem cells, but also pro-
moted differentiation toward cells expressing neuronal and
glial markers.
As shown in Figs. 7 and 8, carbon nanotube patterns can
be used to guide growth and alignment of MSCs [85]. The
MSCs exhibited preferential growth on CNT patterns, and
the cell culture results suggested that the CNT patterns did
not have a harmful effect on the MSCs. The results clearly
show that CNT patterns have enormous potential as a new
platform for basic research and applications using stem
cells.
Stem cell differentiation is closely associated with their
microenvironment. The regulation of stem cells depend
largely on their interaction with a highly specialized
microenvironment or niches [86]. Secreted factors, stem
cell–neighboring cell interactions, extracellular matrix
(ECM), and mechanical properties collectively make up the
stem cell microenvironment. The niche secretes appropriate
chemicals to direct the differentiation and development of
stem cells. For example, Adams et al. [87] has identiﬁed the
elements of the microenvironment that control the behavior
of mammalian stem cells. Mineral components are impor-
tant to stem cell localization; matrix components are
important to constraint of stem cells; and bone-forming
osteoblasts are also very important to the support and pro-
liferation of stem cells, the calcium-sensing receptor,
located on the surface of HSCs and other cells, is critical to
stem cells ﬁnding their niche.
A key challenge in stem cell microenvironment research
is to develop an in vitro system that accurately imitate the
in vivo microenvironment [88]. Nanotechnology can be
utilized to create in vivo-like stem cell microenvironment
to determine mechanisms underlying the conversion of an
undifferentiated cells into different cell types [89]. A better
solution is currently under investigation: growing the stem
cells on a so-called ‘‘lab-on-a-chip’’ [90]. This is a silicon
chip with nanoreservoirs. The chip surface contains about a
Fig. 7 Schematic diagram
depicting the directed growth of
MSCs on large-scale carbon
nanotube patterns. a patterning
of non-polar 1-octadecanethiol
(ODT) SAM while leaving
some bare Au area. b Selective
adsorption and precision
alignment of CNTs directly onto
a bare Au surface. c Passivation
of the exposed bare Au surface
between the aligned CNTs with
ODT. d Directed growth of
MSCs onto the carbon nanotube
patterns [85]
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500 nm across. A reservoir holds a small amount of liquid
chemicals similar to what the stem cells would be exposed
to in the niche. Each reservoir is sealed with a lipid bilayer
equivalent to a cell membrane. These reservoir bilayers
also contain the same voltage-gated channels found in
cells. A small charge of electricity can then be applied to
any individual reservoir to open the channels allow the
chemicals to spill out, delivering them to any particular
stem cell at any speciﬁed time of development. The na-
noreservoir chip technology also allows the possibility of
growing cells layer by layer, making compound tissues,
which are otherwise difﬁcult to produce.
Substrate topography inﬂuences a wide range of stem
cell behaviors in a manner distinct from surface chemistry.
One physical difference in the topography of divergent
basement membranes is the size of pores and ridges.
In vivo, cells never see ﬂat surfaces: on the nanoscale, no
basement membrane, or extracellular matrix is ﬂat. The
great majority of features in the extracellular environment
are in the submicron to nanoscale range, ensuring that an
individual cell is in contact with numerous topographic
features [25, 91]. For example, Edgar et al. [92] focused on
the thickness of polypyrrole ﬁlms and their potential as a
biocompatible material for rat MSCs. Others have
investigated the potential of electrospun porous scaffolds
of randomly oriented 500–900 nm diameter nanoﬁbers for
cartilage repair [57, 93]. Nanoﬁbrous structures can
favorably modulate osteoblast, osteoclast, and ﬁbroblast
activities toward implant and/or scaffold materials [94].
Nanoﬁbrous matrices are introduced as scaffolds that may
have a better structural resemblance to target tissues than
their bulk counterparts, because major components in tis-
sues are nanoscale structures and cells appear to attach and
proliferate better on nanoscale structures than on bulk
materials. So far there is a rapidly growing interest in
synthesis of natural polymer based nanoﬁbers because of
their proven biocompatibility and resorbable biodegrada-
tion products. Advantageous attributes of natural polymers
include hydrophilicity, nontoxicity, less immune reaction,
as well as enhanced cell adhesion, and proliferation.
However, fabrication of natural polymer nanoﬁbers by
electrospinning is challenging. Chitosan and alginate, two
abundant natural polymers, have been widely used in tissue
engineering, but none had been fabricated into nanostruc-
tured matrices until in recent 2 years. Li and Zhang [95]
reported that they successfully used Chitosan- and alginate-
based nanoﬁbrous matrices to mimic the ECM of articular
cartilage that primarily consists of type II collagen
and proteoglycans (glycosaminoglycan, GAG). A kind of
Fig. 8 a MSC adhesion on various nanostructures and self-assembled
monlayer (SAM) on Au or SiO2 surfaces. MSC spreading was
characterized by measuring the cell area in actin ﬁlament ﬂuorescence
images. The surfaces studied are SWCNTs on Au (SWCNT/Au),
SWCNTs on cystamine SAM on Au (SWCNT/Cys), SWCNTs on
MHA SAM on Au (CNT/MHA), SWCNTs on APTES SAM on SiO2
(CNT/APTES), ZnO nanowires on Au (ZNO/Au), V2O5 nanowires on
cysteamine SAM on Au (V2O5/Cys), OTS SAM on SiO2 (OTS/SiO2),
and APTES SAM on SiO2 (APTES/SiO2). b Fluorescence microscope
image of actin ﬁlaments in MSCs adsorbed onto SWCNT patterns on
Au surface. SWCNTs were adsorbed onto bare Au with ODT SAM as
passivation layer. c Optical microscope image of MSCs adhered ontp
mwCNTs/ODT SAM patterns (50 lm wide mwCNT regions and
100 lm wide ODT regions) with ODT passivation after 24 h of cell
culture. The mwCNT regions appear as dark areas around the MSCs.
d Elongation of MSCs on bulk swCNT substrates or swCNT line
patterns as in (b). e Fluorescence microscope image of vinculins
represaenting focal adhesions of MSC adsorbed onto swCNT patterns
on Au. f Immunoﬂuorescence image of the ﬁbronectins adsorbed on
the swCNT patterns on Au substrate [85]
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123nanopit template was etched with the special conglomer-
ation surface and nanopits less than 100 nm in diameter. In
the ﬂat culture surface and nutrient medium of nanopit
align ordered, the stem cell could not differentiate. But in
the nutrient medium concurrent of ordered and unordered
align nanopit, the stem cell could grow to the calcify
ossature cell. The stem cell could obtain the signal from the
template. The surface of the transplanted tissue is the
nanoengineering surface, it can induce the stem cell grow
into the ossature. Obviously, surface character play an
important role on stem cell development and it is a relative
simple way to control stem cell.
Application of Nanotechnology in Stem Cell Therapy
Nanotechnology plays more and more important role in
stem cell therapy. Tysseling-Mattiace et al. [96] reported
that paralyzed mouse which is lead by spinal cord injury
recover walking function after injection the nanoﬁber
which conjugating the laminin and nerve stem cell 6 weeks
later. The neurite sprouting/guiding epitope combine the
integrin which adjust cell differentiation could actuate
signal and stimulate neuraxis extension. After 24 h, nerve
stem cells begin to differentiate on damage position and
generate new neuron which inhibit colloid cell form cica-
trix and help recovery nerve. The nanoﬁber was degraded
after 8 weeks. The experimental mice suffer sever spinal
cord injury similar to human extremely sever damage
caused by trafﬁc accident. The regenerate method has great
potential application in disease therapy such as Parkinson
disease, apoplexy, cardiopathy, diabetes, and so on [97].
Nitric oxide (NO) has been shown to inhibit neointimal
hyperplasia after arterial interventions in several animal
models. NO-based therapies have great potential in clinical
application. Combining nanoﬁber delivery vehicles with
NO chemistry can create a novel, more potent NO-releas-
ing therapy that can be used clinically. Primary experiment
showed that the spontaneously self-assembling NO-
releasing nanoﬁber gels can be used to prevent neointimal
hyperplasia [98, 99].
Challenges and Prospects
In recent years, application of nanotechnology in stem cells
has made great advances, which is becoming an emerging
interdisciplinary ﬁeld. Stem cell nanotechnology is devel-
oping toward imaging, active tracing, and controllable
regulation of proliferation and differentiation of stem cells.
However, like any emerging ﬁeld, stem cell nanotechnol-
ogy also face many challenges. The mechanism of
interaction between nanomaterials and stem cells is still not
clariﬁed well, nanomaterials and nanostructures are how to
affect the function of stem cells, nanomaterials inside stem
cells are how to be metabolized, which are great chal-
lenges. How to use current knowledge and principles to
fabricate novel multifunctional or homogenous nanostruc-
tures, the processing, characterization, interface problems,
high quality nanomaterials availability, nanomaterials tai-
loring, and the mechanisms governing the behavior of these
nanoscale composites on the surface of stem cells are also
great challenge for present existing techniques. The ips
cells were prepared by using HIV virus-based gene deliv-
ery system. Using nanomaterials-based gene delivery
system to replace virus-based gene delivery system will
also a great challenges. However, stem cell nanotechnol-
ogy shows great attracting prospects, stem cells are
developing toward application of generative medicine, we
believe that stem cell nanotechnology will be broadly
applied in treatment of injuries and degenerative diseases
in the near future.
Concluding Remarks
Stem cell nanotechnology provides novel chance for stem
cellsresearchanddevelopment,speedsuptheexplorationof
application of stem cells in generative medicine. Nanoma-
terials such as quantum dots, ﬂuorescent CNTs and
ﬂuorescent MNPs, etc., have been used for imaging and
tracing, gene or drug delivery, scaffolds for tissue engi-
neering, designed nanostructures have been used to regulate
the proliferation anddifferentiationof stem cells, which will
speed up the understanding and controlling the microenvi-
ronmental signals, helping to solve the current bottleneck
problems of stem cells-based therapy. Although stem cell
nanotechnology faces many challenges, marriage of stem
cells and nanotechnology have exhibited attracting techno-
logical prospects, and will dramatically advance our ability
to understand and control stem cell-fate decisions and
develop novel stem cell technologies, which will eventually
lead to stem cell-based therapeutics for human diseases.
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